- Home
- ABP vs BOLT Comparison
ABP vs BOLT Comparison
Compare ABP & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABP | BOLT |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 10.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABP | BOLT |
|---|---|---|
| Price | $3.94 | $5.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 18.1K | ★ 31.5K |
| Earning Date | 02-10-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,195,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 50.00 | N/A |
| 52 Week Low | $4.51 | $4.41 |
| 52 Week High | $153.90 | $12.60 |
Technical Indicators
Market Signals| Indicator | ABP | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 34.81 | 49.91 |
| Support Level | $4.55 | $5.00 |
| Resistance Level | $5.08 | $5.71 |
| Average True Range (ATR) | 0.44 | 0.39 |
| MACD | -0.24 | -0.02 |
| Stochastic Oscillator | 13.85 | 26.96 |
Price Performance
Historical ComparisonAbout ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.